[go: up one dir, main page]

NO20064151L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20064151L
NO20064151L NO20064151A NO20064151A NO20064151L NO 20064151 L NO20064151 L NO 20064151L NO 20064151 A NO20064151 A NO 20064151A NO 20064151 A NO20064151 A NO 20064151A NO 20064151 L NO20064151 L NO 20064151L
Authority
NO
Norway
Prior art keywords
treatment
active compounds
derivatives
alkyl
new connections
Prior art date
Application number
NO20064151A
Other languages
English (en)
Other versions
NO337281B1 (no
Inventor
Ivan Leo Pinto
Shahzad Sharooq
Neville Hubert Nicholson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20064151L publication Critical patent/NO20064151L/no
Publication of NO337281B1 publication Critical patent/NO337281B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer farmasøytisk aktive forbindelser som er xantinderivater, fremgangsmåter for fremstilling av nevnte derivater, farmasøytiske formuleringer som inneholder de aktive forbindelsene og anvendelse av forbindelsene ved behandling, særlig ved behandling av sykdommer hvor underaktivering av HM74A reseptoren bidrar til sykdommen eller hvor aktivering av reseptoren vil være fordelaktig, som har formel (II); hvori R' er valgt fra: hydrogen og C_alkyl som eventuelt kan være substituert med en eller flere grupper valgt fra CN og CF, Rer valgt fra: C-io usubstituert alkyl, Calkyl substituert med en eller flere grupper valgt fra fluor og CN, Calkenyl, uforgrenet Calkenyl og C^ alkyl substituert med cykloalkyl og Rer valgt fra halogen og CN.
NO20064151A 2004-02-14 2006-09-13 Nye forbindelser, anvendelse derav for fremstilling av et medikament, farmasøytisk formulering og kombinasjon NO337281B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds
PCT/EP2005/001449 WO2005077950A2 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity

Publications (2)

Publication Number Publication Date
NO20064151L true NO20064151L (no) 2006-11-06
NO337281B1 NO337281B1 (no) 2016-02-29

Family

ID=34864831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064151A NO337281B1 (no) 2004-02-14 2006-09-13 Nye forbindelser, anvendelse derav for fremstilling av et medikament, farmasøytisk formulering og kombinasjon

Country Status (25)

Country Link
US (5) US7713982B2 (no)
EP (1) EP1781657B1 (no)
JP (2) JP5001012B2 (no)
KR (1) KR101100601B1 (no)
CN (2) CN101103030B (no)
AR (1) AR047669A1 (no)
AU (1) AU2005212816C1 (no)
BR (1) BRPI0507604A (no)
CA (1) CA2556073C (no)
CY (1) CY1114022T1 (no)
DK (1) DK1781657T3 (no)
ES (1) ES2406732T3 (no)
HR (1) HRP20130406T1 (no)
IL (1) IL177051A (no)
MA (1) MA28357A1 (no)
MY (1) MY148937A (no)
NO (1) NO337281B1 (no)
NZ (1) NZ548496A (no)
PE (1) PE20060317A1 (no)
PL (1) PL1781657T3 (no)
PT (1) PT1781657E (no)
SG (1) SG157242A1 (no)
SI (1) SI1781657T1 (no)
TW (1) TWI350289B (no)
WO (1) WO2005077950A2 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200201260T2 (tr) * 1999-11-12 2002-09-23 Biogen, Inc. Adenosin reseptör antagonistleri olarak polisikloalkilpurinler.
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
EP1781657B1 (en) * 2004-02-14 2013-03-27 GlaxoSmithKline Intellectual Property Development Limited Medicaments with hm74a receptor activity
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006247695B2 (en) 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
BRPI0611784A2 (pt) 2005-06-14 2010-09-28 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e utilização desses compostos
US20060293364A1 (en) 2005-06-28 2006-12-28 Subharekha Raghavan Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007017261A1 (en) * 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
CA2637717A1 (en) * 2006-01-20 2007-08-02 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
KR101083490B1 (ko) * 2006-05-23 2011-11-16 에프. 호프만-라 로슈 아게 피리도피리미딘온 유도체
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
KR20090025261A (ko) * 2006-06-23 2009-03-10 인사이트 코포레이션 Ｈｍ７４ａ 아고니스트로서의 퓨리논 유도체
EP2049544B9 (en) * 2006-06-23 2011-07-20 Incyte Corporation Purinone derivatives as hm74a agonists
AU2008231873B2 (en) * 2007-03-23 2011-11-10 F. Hoffmann-La Roche Ag Aza-pyridopyrimidinone derivatives
ES2527354T3 (es) * 2008-12-08 2015-01-22 Glaxosmithkline Llc Anhidrato de 8-cloro-3-pentil-3,7-dihidro-1H-purina-2,6-diona 2-amino-2-(hidroximetil)-1,3-propanodiol para el tratamiento de enfermedades
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
BR112017016065A2 (pt) * 2015-01-30 2018-04-03 Shanton Pharma Co., Ltd. prevenção ou tratamento de ácido úrico ou doença gotosa
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
US12150975B2 (en) 2016-07-27 2024-11-26 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
US11083199B2 (en) 2017-01-10 2021-08-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
CA3155338A1 (en) * 2019-09-25 2021-04-01 Goldfinch Bio, Inc. Xanthine cb1 inhibitors
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
US20260035370A1 (en) 2023-02-27 2026-02-05 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
AU3725893A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
DE69332634T2 (de) 1992-03-04 2003-05-08 Cell Therapeutics, Inc. Enantiomere hydroxylierte xanthinverbindungen
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JPH09511496A (ja) 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド 細胞内メッセンジャー
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
DE60024604T2 (de) 1999-04-09 2006-08-24 Cell Therapeutics, Inc., Seattle Xanthinderivate und analoge als zellsignalisierung inhibitoren
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
HK1049835B (zh) * 1999-08-31 2005-04-08 范德比尔特大学 A2b腺苷受体的选择性拮抗剂
AU2001276023A1 (en) * 2000-07-21 2002-02-05 Mark B Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
AU2002210521A1 (en) * 2000-09-19 2002-04-02 Novimmune S.A. Use of statins (HMG-CoA reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
NZ528216A (en) 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
EP1377834A2 (en) 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
EP1781657B1 (en) * 2004-02-14 2013-03-27 GlaxoSmithKline Intellectual Property Development Limited Medicaments with hm74a receptor activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2007017261A1 (en) * 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
ES2527354T3 (es) * 2008-12-08 2015-01-22 Glaxosmithkline Llc Anhidrato de 8-cloro-3-pentil-3,7-dihidro-1H-purina-2,6-diona 2-amino-2-(hidroximetil)-1,3-propanodiol para el tratamiento de enfermedades
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
HRP20130406T1 (hr) 2013-06-30
CN101103030B (zh) 2010-10-13
US20100010021A1 (en) 2010-01-14
US7713982B2 (en) 2010-05-11
WO2005077950A2 (en) 2005-08-25
US20100160354A1 (en) 2010-06-24
US8394808B2 (en) 2013-03-12
SI1781657T1 (sl) 2013-07-31
KR101100601B1 (ko) 2011-12-29
PE20060317A1 (es) 2006-06-22
MA28357A1 (fr) 2006-12-01
ES2406732T3 (es) 2013-06-07
AU2005212816C1 (en) 2010-03-04
EP1781657A2 (en) 2007-05-09
AR047669A1 (es) 2006-02-01
IL177051A0 (en) 2006-12-10
IL177051A (en) 2013-01-31
AU2005212816B2 (en) 2009-07-23
US20130150383A1 (en) 2013-06-13
CN101863888B (zh) 2012-07-18
AU2005212816A1 (en) 2005-08-25
CA2556073A1 (en) 2005-08-25
KR20060126772A (ko) 2006-12-08
CN101103030A (zh) 2008-01-09
US8268839B2 (en) 2012-09-18
HK1104530A1 (en) 2008-01-18
PT1781657E (pt) 2013-05-23
NO337281B1 (no) 2016-02-29
PL1781657T3 (pl) 2013-08-30
TW200536537A (en) 2005-11-16
JP2007522176A (ja) 2007-08-09
EP1781657B1 (en) 2013-03-27
US20150080418A1 (en) 2015-03-19
CN101863888A (zh) 2010-10-20
MY148937A (en) 2013-06-14
DK1781657T3 (da) 2013-06-10
JP5020848B2 (ja) 2012-09-05
SG157242A1 (en) 2009-12-29
WO2005077950A3 (en) 2007-04-19
TWI350289B (en) 2011-10-11
US20070135456A1 (en) 2007-06-14
CY1114022T1 (el) 2016-07-27
BRPI0507604A (pt) 2007-07-03
CA2556073C (en) 2012-01-10
JP5001012B2 (ja) 2012-08-15
JP2008120831A (ja) 2008-05-29
NZ548496A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
NO20064151L (no) Nye forbindelser
CN104837825B (zh) 鲁顿酪氨酸激酶抑制剂
ES2977656T3 (es) Inhibidores de KDM1A para el tratamiento de enfermedades
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20092342L (no) Azaspiroderivativater
NO20090328L (no) Nye forbindelser 385
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20090327L (no) Nye forbindelser 384
NO20081844L (no) Terapeutiske forbindelser
CN106879256B (zh) 2-氨基-苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素e合成酶抑制剂的应用
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
NO20082496L (no) Pyrazinderivater
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
CA2954751A1 (en) Indoles for use in influenza virus infection
CN119874561A (zh) 带电的离子通道阻滞剂及其使用方法
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
NO20056192L (no) Kapaseinhibitorer og anvendelse derav

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXOSMITHKLINE LLC, US

MM1K Lapsed by not paying the annual fees